Suggestions
Maria Belvisi
SVP Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca
Maria Belvisi is a prominent figure in the field of respiratory pharmacology and research. She currently serves as the Senior Vice President (SVP) of Research and Early Development for Respiratory & Immunology in BioPharmaceuticals R&D at AstraZeneca, a position she has held since April 2019.1
Career Highlights
AstraZeneca: Maria joined AstraZeneca in September 2017 as Vice President of Respiratory, Inflammation and Autoimmune (RIA) Innovative Medicines, based in Gothenburg, Sweden.1 In her current role, she leads early-stage research and development in chronic lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and chronic cough.2
Academic Career: Alongside her industry role, Maria is a Professor of Respiratory Pharmacology at Imperial College London, a position she has held since August 2000.1 Her research focuses on the cellular and molecular mechanisms of respiratory diseases, aiming to develop new therapies.2
Previous Experience: Prior to joining AstraZeneca, Maria led a team at Rhône-Poulenc Rorer (now Aventis Pharma) from 1997 to 2000, focusing on respiratory disease.12
Education and Achievements
Maria holds a PhD in Pharmacology from Imperial College London and a BSc in Pharmacology from King's College London.1
Her notable achievements include:
- Elected as an Honorary Fellow of the British Pharmacological Society in 20191
- Served as research director for the European Respiratory Society from 2013 to 20162
- Recipient of several awards, including the British Pharmacological Society AstraZeneca Women in Pharmacology Prize and the Woman in Inflammation Science Award2
Entrepreneurship and Publications
In 2010, Maria co-founded IR Pharma, a preclinical respiratory drug discovery organization, with her colleague Dr. Mark Birrell.12
She has authored numerous scientific papers on respiratory illnesses and treatments, many of which have been widely cited in the field.2
Maria Belvisi's extensive experience in both academia and industry, coupled with her leadership roles and research contributions, have established her as a key figure in respiratory pharmacology and drug development.
Highlights
It is great joining friends, colleagues and peers at #ERSCongress2024 this week. As always, it was inspiring to discuss the latest innovation and advances in respiratory care.
At AstraZeneca, we are dedicated to pioneering solutions in respiratory care, such as early intervention, with the goal of ultimately eliminating COPD as a leading cause of death. This is why I am so proud of our innovative approach to identify symptomatic undiagnosed COPD patients through our partnerships with global lung health check screening programmes. These partnerships are enabling earlier detection of COPD and supporting patient recruitment into clinical trials.
As industry leaders in the field, we continue to drive innovative research to address the underlying drivers of disease to ultimately transform COPD care. Read more from my colleague Robert Fogel, MD about how we are pushing the boundaries of what’s possible in respiratory care:
At AstraZeneca, we see our work as vital to delivering transformative change and aspire to improve the lives of millions of patients living with respiratory diseases worldwide. With these ambitions in mind, we are committed to developing new modalities and exploring underlying drivers of disease, ensuring there are viable solutions at every stage of the respiratory patient journey and across diseases. I encourage you to take a few minutes to read this new article from my colleague Robert Fogel, MD, who shares more on how our innovative approach can reduce the impact of respiratory diseases on healthcare systems, society and the planet: https://bit.ly/3Tcw0Cr #ERSCongress2024
